[Funding News] PreciseDx Raises $20.7 Million Series B Funding

PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, has raised $20.7 million in Series B funding, bringing its total funding to $31.5 million led by Eventide Asset Management, with other participants in include Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.

Read also – [Funding News] Grid Status Raises $8 Million Funding led by Energize Capital

Following the completion of two successful validation studies (analytical and clinical), PreciseDx received approval under the CLIA Standard and underwent CLEP NYSDOH review for the PreciseBreastTM assessment. The company also published a Cost Impact Study in the Journal of Medical Economics and added new key collaborations, including UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health. These accomplishments preceded the funding announcement.

Read also – [Funding news] Great Many Secures $3.6Million in Pre-Seed Funding

“Our team continues to advance breast cancer diagnostics by delivering faster, more accurate data, in a cost-efficient method. This allows clinical care teams to make better informed clinical decisions resulting in improved patient outcomes,” said Eric Converse, Founding Board Member of PreciseDx. “This capital infusion sets the stage for our next phase of continued in-depth clinical trials to validate PreciseBreast™ in a specific clinical setting and market entry point.”

“We’re excited about PreciseDx, the milestones accomplished to date, and the potential for improving patient care in the near future,” said Westley Dupray, CFA, Research Analyst, Principal at Eventide. “We expect this financing will help accelerate the validation process for PreciseBreast™ and its potential to improve patient risk assessments, clinical outcomes, and healthcare efficiency.”

About PreciseDx

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.